The Lung Cancer Research Foundation (LCRF) announces today a new funding mechanism: the 2025 LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The Request for ...

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Continued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP ...

Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment ...

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

Originally designed as glucose-lowering medications, SGLT2 inhibitors provide benefits across the cardio-renal-metabolic ...

Dr Amit Rauthan, Head, Department and Consultant, Medical Oncology and Hemato-Oncology, Manipal Hospital, explains how the advancements in oncology are offering hope by transforming cancer into a more ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there ...

In contrast, when using the traditional race-adjusted creatinine-based equation (eGFRcr-ASR), the HR was 2.8 (95% CI, 1.6–4.9 ...

Sibeprenlimab clinically reduces proteinuria in adults with immunoglobulin A nephropathy (IgAN), according to data from a prespecified analysis of the phase 3 VISIONARY trial. The findings were ...

EGFR inhibitors such as Erbitux and Gilotrif show potential in laboratory and mouse studies in treating melanoma with a ...